Shares of Vivus Inc. surged 77.5 percent Thursday following an overwhelmingly positive vote by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for its weight loss candidate Qnexa (phentermine/topiramate). (See BioWorld Today, Feb. 23, 2012.)